Regeneron Pharmaceuticals, Inc.

-18.22 (-2.93%)
Debt Financing / Related

Regeneron And Ultragenyx Collaborate To Commercialize Evkeeza® Outside The United States

Published: 01/07/2022 12:32 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States.
Regeneron Pharmaceuticals Inc - Will Receive a $30 Million Upfront Payment and is Eligible to Receive Up to $63 Million in Additional Milestones.
Regeneron Pharmaceuticals Inc - Regeneron Will Continue to Solely Commercialize Evkeeza in U.S.regeneron Pharmaceuticals Inc - Ultragenyx Will Receive Rights to Develop, Commercialize and Distribute Evkeeza Outside of U.S.regeneron Pharmaceuticals Inc - in Countries Outside of U.S., Ultragenyx Will Be Responsible for Commercialization Efforts.
Regeneron Pharmaceuticals Inc - Ultragenyx Will Share in Certain Costs for Global Trials Led by Regeneron.
Regeneron - Granted Ultragenyx an Exclusive Option to Negotiate a Separate Agreement Related to Co's Investigational Antibody for Treatment of Fop.